HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.

ABSTRACT: Resistance to HER2-targeted therapies remains a major obstacle in the treatment of HER2-overexpressing breast cancer. Understanding the molecular pathways that contribute to the development of drug resistance is needed to improve the clinical utility of novel agents, and to predict the success of targeted personalized therapy based on tumor-specific mutations. Little is known about the clinical significance of HER family mutations in breast cancer. Because mutations within HER1/EGFR are predictive of response to tyrosine kinase inhibitors (TKI) in lung cancer, we investigated whether mutations in HER family kinase domains are predictive of response to targeted therapy in HER2-overexpressing breast cancer. We sequenced the HER family kinase domains from 76 HER2-overexpressing invasive carci

SUBMITTER: Boulbes DR 

PROVIDER: S-EPMC4815926 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature